RecruitingRecruiting
The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
NCT07038304 · University Medical Center Groningen
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Oligometastatic Directed Radiotherapy for Patients With Castration Resistant Prostate Cancer
About this study
The primary aim of this study is to test the hypothesis that the addition of MDRT to standard of care (ADT or ADT + chemotherapy or ARTA) in well-selected PCa patients with oligometastatic progressive disease, defined on PSMA PET, prolongs the radiological progression-free survival (rPFS) and postpones the start of next line systemic therapy (NEST). Patients included in this study already have an indication to start NEST, and any delay introduced by adding MDRT will result in a net benefit for the patients.
Primary objectives include: Postponement of the start of next line systemic treatment (NEST), and enhancement of the radiological progression-free survival (rPFS) In this single arm multicenter prospective phase II trial, we aim to include 35 patients with omCRPC (1-3 metastases and/or local recurrence) who will be treated with MDRT to the visible progressive lesions (up to max of 3). Progression is based on PSMA PET.
Eligibility criteria
Inclusion Criteria:
* Adenocarcinoma of the prostate.
* mCRPC setting, with testosterone level \< 50 ng/dl or 1.7 nmol/l.
* Oligoprogressive disease diagnosed on PSMAscan; defined as the progression of pre-existing metastatic disease, and/or the appearance of new metastases and/or the appearance of a local relapse with a maximum of 3 lesions in total.
* Patients currently treated with ADT, whether combined with another systemic treatment such as ARTA, chemotherapy.
* For patients treated with chemotherapy, the course should be completed or stopped before start MORT - In case of treatment with ARTA, a minimal of 3 months response (PSA or clinical response).
* WHO performance status 0-2.
* Age \> = 18 years old.
* Patiënt should be presented at the multidisciplinary tumor board of the local hospital in which the therapy will be given.
* Before patiënt registration, written informed consent must be given according to ICH/GCO and national/local regulations.
Exclusion Criteria:
* Serum testosterone level \> 50 ng/ml or \> 1.7 nmol/l.
* Presence of more than 3 progressive/new metastatic lesions and/or local recurrence (which counts for 1 lesion).
* Active malignancy other than prostate cancer that can potentially interfere with the interpretation of the trial, except non-melanoma skin cancer or non-invasive urothelial cell carcinoma.
* Local recurrence in the prostate after previous radiotherapy
* Previous treatments (RT, surgery) or comorbidities making new treatment with MDRT impossible.
* Disorder precluding understanding of trial Information or informed consent or signing informed consent.
* Evidence of PSMA-negative disease.
Study design
Enrollment target: 35 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-01-03
Estimated completion: 2029-01-03
Last updated: 2025-06-26
Interventions
Radiation: Metastasis directed radiotherapy
Primary outcomes
- • NEST-FS (6, 12-and 24-months)
- • rPFS (6, 12-and 24-months)
Sponsor
University Medical Center Groningen · other
Contacts & investigators
ContactShafak Aluwini · contact · s.al-uwini@umcg.nl · +31625649975
All locations (2)
UMC GroningenRecruiting
Groningen, Netherlands
Radboud UmcNot Yet Recruiting
Nijmegen, Netherlands